Year All202620252024202320222021202020192018201720162015201420122011 Mar 14, 2019 Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors Mar 7, 2019 Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology Mar 6, 2019 Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights Feb 21, 2019 Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference Feb 7, 2019 Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan Nov 13, 2018 Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C Nov 7, 2018 Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights Oct 26, 2018 Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus Oct 8, 2018 Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting Oct 4, 2018 Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders